The media database brings together all published information on platforms and products, as well as financial and corporate news.
Join our mailing list.
09/26/2018
Adocia to Present Five Abstracts at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD)
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
09/20/2018
“Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-Rapid Insulin BioChaperone® Lispro (BCLIS) versus Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes” (Poster 998), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
09/05/2018
Adocia announces positive topline results for the first clinical study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
08/08/2018
American Arbitration Association Panel Finds In Favor Of Adocia In First Phase Of Arbitration Against Eli Lilly
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
07/12/2018
Ultra-rapid BioChaperone® Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes. Diabetes Obes Metab., 2018;20(11):2627-2632.
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
06/26/2018
BioChaperone® Glucagon, a stable ready-to-use liquid glucagon formulation, is well tolerated and quickly restores euglycemia after insulin-induced hypoglycemia, by Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/26/2018
BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations, Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/25/2018
BioChaperone® Technology Enables the Development of Pramlintide-Prandial Insulin Combinations, Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/22/2018
“Pooled Analysis of Clinical Trials Investigating the Pharmacokinetics (PK) of Ultra-Rapid Insulin BioChaperone® Lispro (BCLIS) versus Lispro (LIS) in Subjects with Type 1 (T1D) and Type 2 (T2D) Diabetes” (Poster 998), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/22/2018
“Better Postprandial Glucose (PPG) Control with BioChaperone® Combo (BC Combo) than with Lispro Mix25 (LMx) or separate Glargine & Lispro (G+L) Administration in Subjects with Type 2 Diabetes (T2DM)” (Poster 1001), presented by Dr. Tim Heise, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/22/2018
BioChaperone® Glucagon, a stable ready-to-use liquid glucagon formulation, is well tolerated and quickly restores euglycemia after insulin-induced hypoglycemia, by Dr. Grégory Meiffren, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/22/2018
“The Ultra-Rapid Insulin (URI) BioChaperone® Lispro (BCLIS) shows Favorable Pharmacodynamics (PD) and Pharmacokinetics (PK) vs Faster Aspart (FIA) and Insulin Aspart (ASP) in Insulin Pumps (CSII)” (Poster 1035), presented by Dr. Bruce W. Bode, 78th Scientific Sessions of the American Diabetes Association, 22-26 June 2018, Orlando, FL (USA)
06/22/2018
“BioChaperone® Lispro, une formulation ultra-rapide d’insuline lispro, améliore le contrôle glycémique post-prandial de sujets diabétiques de type 1 traités par de multiples injections quotidiennes d’insuline pendant 14 jours.” (Abstract CAD-19), presented by Dr. Grégory Meiffren, 2018, Société Francophone du Diabète (France)
06/22/2018
“Ultra-rapid BioChaperone® Lispro ameliorates postprandial blood glucose (PPG) control compared to Humalog in subjects with type 1 diabetes mellitus” (Poster PI005), presented by Dr G. Anderson, American Society for Clinical Pharmacology & Therapeutics (ASCPT)
06/15/2018
Ultra-Rapid BioChaperone® Lispro ameliorates postprandial blood glucose control compared with Humalog(R) in subjects with type 1 diabetes mellitus, Dr. Grit Anderen, 76th Scientific Sessions American Diabetes Association 10-14 June 2016, New Orleans, LO (USA)
06/14/2018
Adocia to Present Six Abstracts at the American Diabetes Association® 78th Scientific Sessions
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
06/11/2018
BioChaperone® Combo (BC Combo) improves postprandial glycemia vs. Humalog® Mix 75/25™ (HMx) in people with type 1 diabetes mellitus (T1DM, Dr. Steven V. Edelman, 76th Scientific Sessions American Diabetes Association 11-13 June 2016, New Orleans, LO (USA)
06/01/2018
Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin Glargine
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
05/02/2018
Adocia to hold conference call in regard to the Strategic Alliance for BioChaperone® Combo and BioChaperone® Lispro in China with Tonghua Dongbao
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
04/26/2018
Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone®Combo and BioChaperone® Lispro in China.
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
04/16/2018
Adocia initiates First-in-Human Clinical Study of BioChaperone® Pramlintide Insulin in people with type 1 diabetes
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
02/17/2018
BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
02/14/2018
BioChaperone® Lispro, an Ultra-Rapid Insulin Lispro formulation improves post-prandial blood glucose control in a 14-day multiple daily insulin injection study in subjects with T2DM, Dr. Grégory Meiffren, February 14-17, 2018, ATTD, Vienna (Austria)
01/25/2018
Adocia Announces Positive Topline Data From a Dose-Proportionality Study of BioChaperone® Combo in People with Type 2 Diabetes
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
12/06/2017
Adocia announces positive topline study results comparing ultra-rapid insulin BioChaperone® Lispro with Novolog® and Fiasp® in people with type 1 diabetes
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
11/20/2017
“Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Excursions vs. Insulin Lispro (LIS) in a 14-Day Treatment Study in Subjects with Type 1 Diabetes (T1DM)” (Poster 964) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
10/20/2017
“Ultra-rapid BioChaperone® Lispro (BCLIS) Improves Postprandial Blood Glucose (PPG) Control vs. Insulin Lispro (LIS) in a14-Day Treatment Study in Subjects with Type 2 Diabetes (T2DM)” (Poster 994) presented by Dr. Tim Heise, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
09/20/2017
“Proportional Dose-Exposure Relationship of Ultra-rapid BioChaperone® Lispro (BCLIS) in Healthy Japanese Subjects” (Poster 996), presented by Dr. Grégory Meiffren, 77th Scientific Sessions of the American Diabetes Association, 9-13 June 2017 in San Diego, CA (USA)
09/05/2017
Adocia Announces Two Data Presentations at the 53rd Annual Meeting of the European Association for the Study of Diabetes
![Icon check](https://www.adocia.com/composants/themes/adocia/inc/assets/img/icon-download-blue.png)
06/14/2017
Adocia announces financial results for the third quarter 2017
Join our mailing list. Subscribe